Last reviewed · How we verify

RASS inhibitors and/or RAS blockers

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · Phase 3 active Small molecule

RASS inhibitors and/or RAS blockers is a RASS inhibitor / RAS blocker (ACE inhibitor, ARB, direct renin inhibitor, or aldosterone antagonist) Small molecule drug developed by Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia. It is currently in Phase 3 development for Hypertension, Heart failure, Chronic kidney disease. Also known as: renin-angiotensin-aldosterone system inhibitor.

RASS inhibitors and RAS blockers suppress the renin-angiotensin-aldosterone system to reduce vasoconstriction, lower blood pressure, and decrease sodium retention.

RASS inhibitors and RAS blockers suppress the renin-angiotensin-aldosterone system to reduce vasoconstriction, lower blood pressure, and decrease sodium retention. Used for Hypertension, Heart failure, Chronic kidney disease.

At a glance

Generic nameRASS inhibitors and/or RAS blockers
Also known asrenin-angiotensin-aldosterone system inhibitor
SponsorAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Drug classRASS inhibitor / RAS blocker (ACE inhibitor, ARB, direct renin inhibitor, or aldosterone antagonist)
TargetRenin-angiotensin-aldosterone system components (ACE, angiotensin II receptor type 1, renin, or aldosterone receptor)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

These agents work by blocking either angiotensin II formation (ACE inhibitors, direct renin inhibitors) or angiotensin II receptor binding (ARBs), or by blocking aldosterone (aldosterone antagonists). By inhibiting this hormonal cascade, they reduce peripheral vascular resistance, decrease blood volume, and improve cardiac remodeling, making them effective for hypertension and heart failure.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about RASS inhibitors and/or RAS blockers

What is RASS inhibitors and/or RAS blockers?

RASS inhibitors and/or RAS blockers is a RASS inhibitor / RAS blocker (ACE inhibitor, ARB, direct renin inhibitor, or aldosterone antagonist) drug developed by Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, indicated for Hypertension, Heart failure, Chronic kidney disease.

How does RASS inhibitors and/or RAS blockers work?

RASS inhibitors and RAS blockers suppress the renin-angiotensin-aldosterone system to reduce vasoconstriction, lower blood pressure, and decrease sodium retention.

What is RASS inhibitors and/or RAS blockers used for?

RASS inhibitors and/or RAS blockers is indicated for Hypertension, Heart failure, Chronic kidney disease, Post-myocardial infarction.

Who makes RASS inhibitors and/or RAS blockers?

RASS inhibitors and/or RAS blockers is developed by Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (see full Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia pipeline at /company/azienda-socio-sanitaria-territoriale-degli-spedali-civili-di-brescia).

Is RASS inhibitors and/or RAS blockers also known as anything else?

RASS inhibitors and/or RAS blockers is also known as renin-angiotensin-aldosterone system inhibitor.

What drug class is RASS inhibitors and/or RAS blockers in?

RASS inhibitors and/or RAS blockers belongs to the RASS inhibitor / RAS blocker (ACE inhibitor, ARB, direct renin inhibitor, or aldosterone antagonist) class. See all RASS inhibitor / RAS blocker (ACE inhibitor, ARB, direct renin inhibitor, or aldosterone antagonist) drugs at /class/rass-inhibitor-ras-blocker-ace-inhibitor-arb-direct-renin-inhibitor-or-aldosterone-antagonist.

What development phase is RASS inhibitors and/or RAS blockers in?

RASS inhibitors and/or RAS blockers is in Phase 3.

What are the side effects of RASS inhibitors and/or RAS blockers?

Common side effects of RASS inhibitors and/or RAS blockers include Hyperkalemia, Hypotension, Cough (ACE inhibitors), Dizziness, Renal function impairment.

What does RASS inhibitors and/or RAS blockers target?

RASS inhibitors and/or RAS blockers targets Renin-angiotensin-aldosterone system components (ACE, angiotensin II receptor type 1, renin, or aldosterone receptor) and is a RASS inhibitor / RAS blocker (ACE inhibitor, ARB, direct renin inhibitor, or aldosterone antagonist).

Related